Lenalidomid Avansor

Lenalidomide, the active ingredient in Lenalidomid Avansor, is an immunomodulatory drug presented as an oral formulation for systemic use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma, in adult patients. The medication works by modifying the immune system and inhibiting tumor growth pathways.

GNH USA supplies Lenalidomid Avansor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across regions.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells. - Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients. - Myelodysplastic Syndromes: reduces transfusion dependence and delays transformation to acute leukemia. - Mantle Cell Lymphoma: contributes to disease control when combined with other therapies.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Nausea: upset stomach with possible vomiting. - Diarrhea: loose stools occurring intermittently. - Rash: mild skin irritation or redness.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

Before initiating Lenalidomid Avansor, several safety considerations should be reviewed. - Pregnancy risk: contraindicated in pregnancy (Category X); effective contraception required. - Thromboembolism risk: assess patient history and consider prophylactic anticoagulation. - Renal function: dose may need adjustment in severe impairment. - Hematologic monitoring: regular CBC to detect neutropenia or anemia. - Drug interactions: review concomitant medications for CYP or immunosuppressive agents. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Lenalidomid Avansor can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce plasma concentrations of lenalidomide. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increased risk of thrombotic or bleeding complications; close monitoring required.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclosporine, tacrolimus): may enhance immunosuppressive effects, increasing infection risk. - Vaccines (live attenuated): reduced efficacy; avoid administration during therapy. - Other antineoplastic agents: overlapping toxicities such as myelosuppression; adjust dosing as needed.